• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Cachexia, Sarcopenia and Muscle >Circulating Activin A predicts survival in cancer patients
【24h】

Circulating Activin A predicts survival in cancer patients

机译：循环激活素A可预测癌症患者的存活率

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Background Several experimental evidences pinpoint the possible role of Activin A (ActA) as a driver of cancer cachexia. Supporting this hypothesis, we showed recently that human cancer cachexia is associated with high ActA levels. Moreover, ActA levels were correlated with body weight loss and skeletal muscle density, two prognostic factors in cancer patients. Our goal was therefore to investigate the value of ActA to predict survival in cancer patients. Methods Patients with colorectal or lung cancer were prospectively enrolled at the time of diagnosis or relapse between January 2012 and March 2014. At baseline, patients had clinical, nutritional, and functional assessment. Body composition and skeletal muscle density were measured by CT scan, and plasma ActA concentrations were determined. Overall survival (OS) was analysed since inclusion to 24 months later. Results Survival data were available for 149 patients out of 152. Patients with high ActA (?￠???￥408 pg/mL) had lower OS than those with low levels, regardless the type of cancer (OS in colorectal cancer, 50% vs. 79%, P < 0.05; and in lung cancer, 27% vs. 67%, P = 0.001). The multivariable analysis confirmed the prognostic value of ActA independently of tumour stage or inflammatory markers, particularly in lung cancer. Low muscularity was also an independent prognostic factor. Conclusions Our study demonstrates that high ActA level is an independent prognosis factor of survival in cancer patients. More than a basic marker of the severity of the neoplastic disease or of the inflammatory process, ActA seems to influence survival by contributing to the development of cachexia and loss of skeletal muscle mass.
机译：摘要背景一些实验证据明确了激活素A（ActA）作为癌症恶病质的驱动因素的可能作用。支持这一假设的研究，我们最近表明，人类癌症恶病质与高ActA水平相关。此外，ActA水平与体重减轻和骨骼肌密度相关，这是癌症患者的两个预后因素。因此，我们的目标是研究ActA预测癌症患者生存的价值。方法在2012年1月至2014年3月的诊断或复发时，对大肠癌或肺癌患者进行前瞻性研究。在基线时，对患者进行临床，营养和功能评估。通过CT扫描测量身体成分和骨骼肌密度，并测定血浆ActA浓度。自纳入以来至24个月后，分析了总生存期（OS）。结果在152名患者中，有149名患者获得了生存数据。ActA高水平（≥408pg / mL）的患者的OS低于低水平的患者，而与癌症的类型无关（结肠直肠癌的OS为50％）。 vs. 79％，P <0.05;在肺癌中，分别为27％和67％，P = 0.001）。多变量分析证实了ActA的预后价值与肿瘤分期或炎性标志物无关，尤其是在肺癌中。肌无力也是一个独立的预后因素。结论我们的研究表明，高ActA水平是癌症患者生存的独立预后因素。 ActA不仅是肿瘤疾病或炎症过程严重程度的基本标志，而且似乎通过促进恶病质的发展和骨骼肌质量的丧失而影响生存。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号